

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## DIAGNOSTICS ASSESSMENT PROGRAMME

### Equality impact assessment – Guidance development

#### Fluorouracil chemotherapy: the My5-FU assay for guiding dose adjustment

##### Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

It was identified at scoping that people with cancer are covered by the disability provision of the equality act from the point of diagnosis. People who may be at greater risk of 5-FU toxicity include people with impaired liver function, people with impaired renal function, people whose body surface area is outside the standard range for dosing 5-FU, and those who have a less favourable performance status (including older people) prior to commencing chemotherapy. The Committee considered evidence on the clinical effectiveness of the My5-FU assay and noted that, because of insufficient evidence, it was not possible to determine whether the use of the My5-FU assay could have a differential impact on the subgroups of people who may be at greater risk of 5-FU toxicity. The Committee therefore recommended further research to determine the clinical effectiveness of using the My5-FU assay for people with cancer who are receiving fluorouracil chemotherapy.

2. Have any other potential equality issues been raised in the second assessment subgroup meeting (if held) and in the evidence assessment and analysis report, and, if so, how has the Committee addressed these?

No additional potential equality issues were raised during the assessment.

3. Have any other potential equality issues been identified by the

Committee, and, if so, how has the Committee addressed these?

No other potential equality issues were identified by the Committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No.

7. Have the Committee's considerations of equality issues been described in the diagnostics consultation document, and, if so, where?

The Committee's considerations of the potential equality issues are described in section 6.8 of the diagnostics consultation document.

**Approved by Associate Director:** Carla Deakin

**Date:** 07/10/2014

## Diagnostics guidance document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No additional potential equality issues were raised during consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The recommendations did not change after consultation.

3. If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

The recommendations did not change after consultation.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

The recommendations did not change after consultation.

5. Have the Committee's considerations of equality issues been described in the diagnostics guidance document, and, if so, where?

The Committee's considerations of the potential equality issues are described in section 6.8 of the diagnostics guidance.

**Approved by Associate Director:** Carla Deakin

**Date:** 07/10/2014